July 22, 2017 5:16 PM ET

Healthcare Equipment and Supplies

Company Overview of Oxford Immunotec Global PLC

Company Overview

Oxford Immunotec Global PLC, a diagnostics company, focuses on developing and commercializing proprietary tests for the management of immune-regulated conditions. Its development activities principally focus on the areas of infectious diseases, transplantation, autoimmune and inflammatory disease, and immune-oncology. The company develops its products using its T-SPOT technology platform, which enables the measurement of responses of specific immune cells to inform the diagnosis, prognosis, and monitoring of patients with immune-regulated conditions. It offers T-SPOT.TB test used to test for tuberculosis. The company markets its T-SPOT.TB test through a direct sales force in the United State...

115D Innovation Drive

Milton Park

Abingdon,  OX14 4RZ

United Kingdom

Founded in 2002

431 Employees

Phone:

44 1235 442780

Fax:

44 1235 442781

Key Executives for Oxford Immunotec Global PLC

Chief Executive Officer & Executive Director
Age: 43
Total Annual Compensation: $370.4K
Chief Financial Officer
Age: 57
Total Annual Compensation: $300.0K
Chief Operations Officer
Age: 55
Total Annual Compensation: $293.5K
Chief Commercial Officer
Age: 56
Total Annual Compensation: $347.0K
Compensation as of Fiscal Year 2016.

Oxford Immunotec Global PLC Key Developments

Oxford Immunotec Global PLC Names Karen Koski as Head of Strategy and Investor Relations

Oxford Immunotec Global PLC announced the appointment of Karen Koski as Head of Strategy and Investor Relations. The newly created position will report directly to Oxford Immunotec's Chief Executive Officer, Dr. Peter Wrighton-Smith. Ms. Koski will join the company on June 21, 2017. Ms. Koski joins the company with a wealth of knowledge and experience in the diagnostics industry. Most recently, Ms. Koski served as a Director and Senior Equity Analyst at BTIG, LLC where she covered companies in the Medical Technology, Life Sciences, and Diagnostics sectors.

Oxford Immunotec Global plc Announces Unaudited Consolidated Earnings Results for the First Quarter Ended March 31, 2017; Provides Revenue Guidance for the Second Quarter and Full Year of 2017

Oxford Immunotec Global PLC announced unaudited consolidated earnings results for the first quarter ended March 31, 2017. Revenue for the first quarter of 2017 was $21.5 million, representing 26% growth over the first quarter 2016 revenue of $17.1 million. On a constant currency basis, revenue growth was 27% versus the prior year period. Net loss for the first quarter of 2017 was $8.1 million, or $0.36 per share, compared to $7.0 million, or $0.32 per share, in the first quarter of 2016. LBITDA for the first quarter was $6.1 million compared to $6.4 million in the first quarter of 2016. Adjusted LBITDA was $7.1 million for the first quarter compared to $5.8 million in the same period in 2016. Loss from operations was $6.956 million against $7.194 million a year ago. Loss before income taxes was $8.025 million against $7.014 million a year ago. The company expects to report revenue of between $24.9 and $25.7 million for the second quarter of 2017. The company continues to expect to report full year 2017 revenue of between $102 and $105 million, representing 19% - 22% year-over-year growth. The company expects revenue to increase 21% to 24% for the year using constant exchange rates.

Oxford Immunotec Global PLC, Annual General Meeting, Jun 06, 2017

Oxford Immunotec Global PLC, Annual General Meeting, Jun 06, 2017, at 06:00 US Eastern Standard Time. Location: Milton Park Innovation Centre, Thames Room 99 Park Drive, Milton Park Abingdon, OX14 4RY United Kingdom Agenda: To elect class I directors; to ratify the audit committee's appointment of Ernst & Young LLP as U.K. Statutory auditor and U.S. independent registered public accounting firm for the fiscal year ending December 31, 2017; to re-appoint Ernst & Young LLP as U.K. statutory auditors; to authorize the audit committee to determine U.K. statutory auditors' remuneration for the fiscal year ending December 31, 2017; to receive the U.K. statutory annual accounts and reports for the fiscal year ended December 31, 2016; to receive and approve U.K. Statutory annual directors' remuneration report for the year ended December 31, 2016; to approve directors' remuneration policy; and to approve the amendment of the 2013 share incentive plan.

Similar Private Companies By Industry

Company Name Region
11 Health Limited Europe
A. Algeo Limited Europe
Abingdon Health Ltd. Europe
Accentus Medical Ltd. Europe
AccuNostics Ltd. Europe

Recent Private Companies Transactions

Type
Date
Target
Merger/Acquisition
October 12, 2016
Immunetics, Inc.
 

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
The Advertising Council, Inc. United States
Rush University United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Oxford Immunotec Global PLC, please visit www.oxfordimmunotec.com. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.